crs-hipec-for-peritoneal-carcinomatosis

A stage 4 cancer diagnosis can feel like a dead end, but there is hope. For certain abdominal cancers that have spread to the peritoneum (lining of the abdomen), a combined surgical approach called Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) offers a chance for long-term survival and even a cure.


What is CRS-HIPEC?


Cytoreductive Surgery (CRS)


This precise and meticulous surgery aims to remove all visible tumors and potentially cancerous tissue from the abdomen, achieving a grossly complete cytoreduction.


Hyperthermic Intraperitoneal Chemotherapy (HIPEC)


After CRS, chemotherapy drugs are circulated and perfused throughout the abdominal cavity in a peritoneal dialysis fluid at a high temperature of 40–42°C to target microscopic cancer cells.


Data and Facts about CRS-HIPEC:


Improved Survival:


Studies show CRS-HIPEC can significantly improve survival rates compared to traditional chemotherapy alone. For example, one study found a median overall survival of 67 months for stage 3 ovarian cancer patients treated with CRS-HIPEC compared to 39 months with chemotherapy.


Curative Potential:


CRS-HIPEC offers the potential for a cure in some cancers, particularly pseudomyxoma peritonei (appendiceal and ovarian origin) and certain types of ovarian cancer.


Multidisciplinary Approach:


The success of CRS-HIPEC relies on a skilled team of surgeons, medical oncologists, anesthesiologists, ICU and critical care specialists, and specialized nurses working together.


Not for Everyone:


CRS-HIPEC is a complex surgery with potential complications like bleeding, infection, bowel issues, and a longer recovery period requiring prolonged ICU or hospital stay. Careful patient selection and thorough pre-operative evaluation are crucial.


Here’s a table summarizing the types of cancers that can benefit from CRS-HIPEC:


Cancer Type Potential Benefit
Pseudomyxoma Peritonei (Appendiceal or ovarian origin) High chance of cure
Ovarian Cancer Improved survival and potential cure in some cases
Colorectal Cancer (Peritoneal Carcinomatosis) Improved survival
Gastric Cancer (Peritoneal Carcinomatosis) Improved survival
Mesothelioma Improved survival

If you have been diagnosed with stage 4 abdominal cancer, discuss CRS-HIPEC with your doctor to see if it’s a potential treatment option for you. Early evaluation and a multidisciplinary approach are key to optimizing outcomes.


Important Disclaimer:


This blog is for informational purposes only and should not be considered medical advice. Always consult with Always consult with your doctor to discuss the best course of treatment for your individual case.


Dr. Harshit Srivastava

Master course in Laparoscopic Liver Resections, Institute of Medical and Minimal Access Surgery Training Mumbai